Arbutus Biopharma (ABUS) Change in Accured Expenses (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Change in Accured Expenses for 14 consecutive years, with -$985000.0 the latest figure, recorded in Q1 2026.

• Quarterly Change in Accured Expenses fell 121.67% year-over-year to -$985000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.6 million (down 297.7% YoY) and the FY2025 annual result came in at -$2.1 million, up 22.24% from the prior year.
• Change in Accured Expenses slipped to -$985000.0 in Q1 2026 per ABUS's latest filing, from $806000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for ABUS reached as high as $4.5 million in Q1 2025 and fell as low as -$7.6 million in Q2 2025.
• A 5-year average of -$372882.4 and a median of $20000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses tumbled 456.04% — and 2025, when it soared 3930.0%.
• Year by year, Change in Accured Expenses stood at $3.8 million in 2022, then plunged by 87.63% to $465000.0 in 2023, then tumbled by 95.7% to $20000.0 in 2024, then surged by 3930.0% to $806000.0 in 2025, then sank by 222.21% to -$985000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$985000.0, $806000.0, and $145000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.